---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pooled phase I/II analysis versus external control"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pooled phase I/II analysis versus external control. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 85 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence/pooled-phase-i-ii-analysis-versus-external-control"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pooled phase I/II analysis versus external control

<a id="heading-3.1.1"></a>

## 3.1.1 Pooled Phase I/II Analysis versus External Control

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Pooled analysis protocols and prespecified external control comparison, September 2025

> “The ongoing Phase I/II AMT-130 clinical trials, from which the data herein are derived, are supplemented by two additional protocols, each with a statistical plan that was discussed with and submitted to the FDA.”
> “The new protocols, among other things, provide for the pooling of data across the ongoing U.S. and EU studies, and also prespecified the pivotal comparison of AMT-130 clinical end points compared to a propensity score-matched external control from the Enroll-HD natural history data set.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.1-2"></a>

#### Comparison of Cohorts 1 and 2 with an Enroll-HD external control as the basis for a BLA

> “Based on interactions with the FDA, it was agreed that data from cohorts 1 and 2 in the Phase I/II studies could be compared to a propensity score-matched external control derived from the Enroll-HD natural history data set, under a prespecified statistical analysis plan, which may serve as the primary basis for a BLA submission.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.1-3"></a>

#### Updated external control comparison in the pooled protocols, September 2026

> “The new protocols, among other things, provide for the pooling of data across the ongoing U.S. and EU studies, and also prespecified the comparison of AMT-130 clinical end points compared to a propensity score-matched external control from the updated Enroll-HD natural history data set.”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Data cutoff of the three-year analysis

> “All data presented here in is as of the data cut off date of June 30, 2025, unless otherwise indicated”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.2-2"></a>

#### Data cutoff of the four-year and updated 36-month analyses

> “Today's announcement comprises results from the ongoing Phase I/II studies at two timepoints, with a data cutoff of June 30, 2026.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.2-3"></a>

#### Enroll-HD dataset releases used as external controls

> “Enroll-HD A – Release date January 2023; Enroll-HD B – Release date September 2025”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.2-4"></a>

#### Clinical trial sites of CT-AMT-130-01 and CT-AMT-130-02

| Study | Sites |
| --- | --- |
| CT-AMT-130-01 | “CT-AMT-130-01 (US)”; “University of Alabama”; “University of California, San Francisco”; “Rush University Medical Center”; “Johns Hopkins University”; “University of Michigan”; “Ohio State University”; “Vanderbilt University Medical Center”; “The University of Texas, Houston”; “Virginia Commonwealth University”; “University of Washington Medical Center”; “CenExel Rocky Mountain Clinical Research, CO”; “University of Arizona – Dept. of Neurology” |
| CT-AMT-130-02 | “CT-AMT-130-02 (UK, Poland)”; “Cardiff University”; “National Hospital for Neurology and Neurosurgery”; “Wojskowy Instytut Medycyny Lotnicze – Klinika Neurologii”; “International Neuro Center” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.2-5"></a>

#### Data cutoff of the 24-month interim analysis, July 2024

> “Across both studies, 24-month follow-up data from a total of 21 patients (n=12 low dose; n=9 high dose) were available for analysis as of a March 31, 2024 cut-off date.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.2-6"></a>

#### Data cutoff of the interim analysis, December 2023

> “The combined U.S. and European data presented in this release are subject to a September 30, 2023 cut-off date and do not include efficacy and biomarker data from the control patients who crossed over to treatment.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Prespecified statistical analysis plan of the three-year analysis

> “Prespecified statistical analysis plan was aligned with and submitted to the FDA in advance of database lock”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.3-2"></a>

#### Propensity score-matched external control reported as the prespecified primary comparison, September 2025

> “The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months compared to a propensity score-matched external control.”
> “In accordance with the prospectively defined statistical analysis plan aligned with, and submitted to, the U.S. Food and Drug Administration (FDA) for this pivotal Phase I/II study, uniQure analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high dose; n=12 low dose) of which 12 patients per dose group had attained 36 months of follow up and were evaluated at that time point.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.3-3"></a>

#### Statistical analysis plan as described in June 2025: propensity score-weighted primary analysis planned

> “The Company plans to use propensity score-weighted external control derived from the ENROLL-HD dataset for the primary analysis and to submit certain sensitivity analyses, including one using a propensity score-matched external control, as additional support.”
> “The FDA also agreed that ENROLL-HD – a large, prospective, longitudinal, natural history study of patients with Huntington’s disease – may be acceptable as the external control dataset for the primary analysis of the trial data along with additional sensitivity analyses using the TRACK-HD/TRACK-ON and PREDICT-HD datasets.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.3-4"></a>

#### Enroll-HD external comparator dataset

> “Prospective data collection, largely contemporaneous with AMT-130 studies”
> “Aligns with clinical measures collected in AMT-130 studies (eg, cUHDRS, TFC, SDMT, SWRT, TMS)”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Rationale for selecting Enroll-HD

> “To date, approximately 33,000 patients have enrolled in ENROLL-HD.”
> “Compared to previously used natural history studies like TRACK-HD and PREDICT-HD, ENROLL-HD offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up.”
> “The Company expects the larger sample size to reduce variability in the external control data and enhance the robustness of the SAP.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.3-6"></a>

#### Propensity score matching method and covariates

> “Primary analysis used restricted full matching with matching weights for Enroll-HD data.”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “Trial participants are matched to people with the most similar propensity score.”
> “Individuals with dissimilar propensity scores are excluded.”
> “(Covariates: baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, SWR)”
> “The same covariates were used in propensity score matching vs Enroll-HD, effectively mitigating potential bias arising from the absence of striatal volume data in Enroll-HD”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Statistical analysis plan of the 48-month analysis with an updated external control

> “48-Month Statistical Analysis Plan Included Updated External Control”
> “Enroll-HD A: ~20,000 participants”
> “Enroll-HD B: ~26,000 participants”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.3-8"></a>

#### Propensity-weighted TRACK-HD, TRACK-ON, and PREDICT-HD external control, July 2024

> “For the first time, uniQure conducted a statistical analysis of clinical outcomes for the 21 treated patients at 24 months compared to an expanded, propensity-weighted external control (n=154) developed in collaboration with the Cure Huntington’s Disease Initiative (CHDI) using data from the TRACK-HD, TRACK-ON and PREDICT-HD natural history studies.”
> “The external control includes patients that met the Phase I/II clinical trial eligibility criteria, and whose data contributions were statistically weighted using propensity scoring to closely match the baseline characteristics of patients treated with AMT-130.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.3-9"></a>

#### Criteria-matched TRACK-HD natural history cohort, December 2023

> “Clinical and functional measurements for treated patients in each dose cohort were compared to baseline measurements, as well as to control patients (up to 12 months) and a non-concurrent criteria-matched natural history cohort.”
> “The natural history cohort was developed by uniQure in collaboration with the Cure Huntington’s Disease Initiative (CHDI) using the TRACK-HD natural history study of patients with early Huntington’s disease.”
> “The cohort includes 31 patients that met the uniQure clinical trial inclusion criteria of Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key eligibility criteria of the high-dose cohort in the three-year analysis

> “Aged 25-65 years”
> “Diagnostic confidence level: 3 or 4”
> “DCL 4, or DCL 3 if individual also meets definition of multidimensional manifest HD or has cognitive symptoms”
> “Total functional capacity: 9-13”
> “HD medications stable prior 3 months”
> “Striatal volumes exceed specified minima”
> “Putamen: ≥ 2.5 cm3/side”
> “Caudate: ≥ 2.0 cm3/side”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.4-2"></a>

#### Selection of the Enroll-HD external control: exclusion criteria

> “Index date outside of effective enrollment window”
> “Missing baseline cUHDRS”
> “No post-baseline visit within Year 1, Year 2, or Year 3 visit windows”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Single administration into the striatum

> “One-time administration via MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen)”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.5-2"></a>

#### Treated participants by dose and imitation surgery controls, July 2024

> “A total of 29 patients received one of two doses of AMT-130 (n=12 low dose; n=17 high dose) and 10 control patients received imitation surgery.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using cUHDRS Change at 36 Months as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary, secondary, and supportive endpoints of the three-year analysis

| Endpoint role | Measure |
| --- | --- |
| Primary endpoint | “Composite Unified Huntington’s Disease Rating Scale (cUHDRS)”; “Change from baseline at 36-months vs Enroll-HD propensity score-matched external control” |
| Secondary endpoints | “Total Functional Capacity (TFC)”; “Symbol Digit Modalities Test (SDMT)”; “Stroop Word Reading Test (SWRT)”; “Total Motor Score (TMS)” |
| Supportive endpoint | “Cerebrospinal fluid (CSF) Neurofilament light chain (NfL) change from baseline at 36-months” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint of the 48-month analysis

> “Change from baseline at 48-months vs Enroll-HD B propensity score-matched external control”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.6.1-3"></a>

##### Components of the cUHDRS as described by the sponsor

| Component | Domain described |
| --- | --- |
| Total Functional Capacity (TFC) | “Impairments in occupation, finance, domestic chores, daily living, and care level” |
| Total Motor Score (TMS) | “Impairment in motor function” |
| Symbol Digit Modalities Test (SDMT) | “Measure of attention, processing speed, and working memory” |
| Stroop Word Reading Test (SWRT) | “Measure of selective attention capacity and processing speed” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-4"></a>

##### Regulatory acceptance of cUHDRS as an intermediate clinical endpoint, December 2024

> “FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-3.1.1.6.1-5"></a>

##### Sponsor statement on the sensitivity of the cUHDRS

> “cUHDRS has been demonstrated to be the most sensitive measurement of clinical progression in Huntington’s disease patients”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.6.1-6"></a>

##### Derivation of the cUHDRS from four UHDRS measures

> “The overall pattern of the correlations and the PCA results indicated that TMS, TFC, SDMT, and SWR had significant overlap, but PBA-apathy did not.”
> “Note the negative sign for (scaled) TMS and the positive sign for all other variables.”
> “The observed difference in the S/N ratio between the cUHDRS and each individual component in TRACK-HD was numerically superior in all cases (e.g., 26%–38% larger than the best individual measure, which was the TMS at 24 and 36 months, respectively)”
> “The results (ICC2,1 = 0.96)9 showed excellent test-retest reliability of the cUHDRS.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-3.1.1.6.1-7"></a>

##### Clinically efficacious slowing on the cUHDRS

> “We have reached consensus that a slowing of clinical decline in the range of 20% to 30% annually on the cUHDRS (≈0.2–0.3 points per year), equivalent to ≈2.4 to 3.5 mo/y of time saved from progression, can be used to define a clinically efficacious treatment in this setting.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-3.1.1.6.1-8"></a>

##### Correlation of the cUHDRS with imaging biomarkers

> “Worse performance in the cUHDRS over time correlated with longitudinal volume decreases in the occipito-parietal cortex and centrum semiovale, whereas lower baseline scores correlated with decreased volume in the basal ganglia and surrounding WM.”
> “The cUHDRS correlates with imaging biomarkers and tracks atrophy progression in HD supporting its biological relevance.”

Source: [Estevez-Fraga et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33471951/)

<a id="topic-3.1.1.6.1-9"></a>

##### Key secondary endpoint: Total Functional Capacity

> “It assesses capacity as opposed to actual performance and consists of a 5‐item interview between a clinician, and the patient and a person familiar with the patient's functioning.”
> “Extensive data from multiple observational studies and clinical trials suggest sensitivity to change over time.”
> “There appears to be a ceiling effect for early stage HD and a floor effect for late stage HD.”
> “Recommendation: The UHDRS‐TFC is suggested for assessing severity of limitation in functional capacity in HD, because it lacks core clinimetric data, namely, test–retest reliability and internal consistency to reach a “recommended” status.”

Source: [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

<a id="topic-3.1.1.6.1-10"></a>

##### Total Functional Capacity as a measure of daily function: investigator statement

> “Total Functional Capacity tracks things that matter the most to patients and families – ability to work, perform household chores and handle daily self-care activities.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.6.1-11"></a>

##### Secondary endpoints: Symbol Digit Modalities Test and Stroop Word Reading Test

> “(1) the symbol digit modalities test (SDMT/sampled cognitive domains: visual attention, working memory, symbolic encoding, and psychomotor speed), in which the total score corresponds to the number of correct responses within 90 seconds”
> “(2) the Stroop color word interference test (sampled cognitive domains: psychomotor speed, cognitive flexibility, response inhibition, and selective attention), which includes 3 conditions (word reading, color naming, interference), each one of which is scored as the total number of items accurately completed within 45 seconds”

Source: [Mestre et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10080408/)

<a id="topic-3.1.1.6.1-12"></a>

##### Supportive endpoint: cerebrospinal fluid neurofilament light chain

> “CSF NfL is a well-characterized, supportive biomarker of neurodegeneration. Elevation in CSF NfL has been shown to be strongly associated with greater clinical severity of Huntington’s disease.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

> “Recent data from HD-CSF study where CSF NfL levels were measured in 71 patients over a two-year period showed an increase over time and a sigmoid trajectory with age.”
> “The study demonstrated early-manifest HD patients will experience increases in CSF NfL of ~10% to 15% per year”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### Natural history of cerebrospinal fluid neurofilament light chain in the HD-CSF cohort

> “mHTT in CSF, as well as NfL in CSF and plasma, all rose detectably within participants over 2 years.”
> “On the basis of simulations of the models in Fig. 2 (D to F), CSF NfL rose in manifest HD by 98.85 pg/ml per year, in preHD by 79.16 pg/ml per year, and in controls by 20.05 pg/ml per year (Fig. 2J).”

Source: [Rodrigues et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7611886/)

<a id="topic-3.1.1.6.1-14"></a>

##### Natural history comparator for cerebrospinal fluid neurofilament light chain, July 2024

> “An independent natural history study demonstrated a 26% increase in CSF NfL at 24 months in patients with early manifest Huntington’s disease (n=19).”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Participants and external controls in the three-year analysis

> “Outcomes for each dose group were compared to a propensity score-matched external control drawn from the Enroll-HD natural history data set (n=940 for high dose; n=626 for low dose).”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.7.1-2"></a>

##### Participants with data at each visit in the three-year analysis, high dose

| Group and endpoint | Baseline | 12 months | 24 months | 36 months |
| --- | --- | --- | --- | --- |
| AMT-130 high dose (cUHDRS and TFC) | “17” | “17” | “15” | “12” |
| PSM external control, cUHDRS | “940” | “715” | “586” | “568” |
| PSM external control, TFC | “940” | “725” | “597” | “583” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants and external controls in the four-year and updated 36-month analyses

> “Twenty-nine patients have been treated with ifezuntirgene inilparvovec (n=17 high dose; n=12 low dose) across the studies’ first two cohorts. The new 36-month analysis now includes 15 high-dose and 12 low-dose patients, with three additional high-dose patients having reached that timepoint since the September 2025 analysis.”
> “The 48-month analysis includes 12 patients at each dose.”
> “Outcomes for the 36-month and 48-month analyses were compared to propensity score-matched external controls (n=1,337 for high dose) from an updated ENROLL-HD natural history dataset with a September 2025 cutoff.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants with data at each visit in the four-year analysis, high dose

| Group and endpoint | Baseline | 12 months | 24 months | 36 months | 48 months |
| --- | --- | --- | --- | --- | --- |
| AMT-130 high dose (cUHDRS and TFC) | “17” | “17” | “15” | “15” | “12” |
| Enroll-HD B, cUHDRS | “1337” | “953” | “760” | “690” | “625” |
| Enroll-HD B, TFC | “1337” | “967” | “772” | “704” | “641” |
| Enroll-HD A, cUHDRS (post hoc) | “619” | “484” | “398” | “355” | “349” |
| Enroll-HD A, TFC (post hoc) | “619” | “492” | “401” | “360” | “364” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.1-5"></a>

##### Participants with cerebrospinal fluid neurofilament light chain samples, through 48 months

| Dose | Base | 1M | 3M | 6M | 9M | 12M | 15M | 18M | 24M | 30M | 36M | 48M |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| High-Dose | “17” | “17” | “16” | “16” | “15” | “14” | “14” | “15” | “15” | “14” | “14” | “11” |
| Low-Dose | “12” | “12” | “11” | “12” | “12” | “12” | “12” | “12” | “12” | “12” | “12” | “11” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.1-6"></a>

##### Participants in the 24-month interim analysis, July 2024

> “uniQure is conducting two multi-center Phase I/II clinical trials of AMT-130 in the U.S. (n=26) and Europe/UK (n=13).”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.7.1-7"></a>

##### Participants in the interim analysis, December 2023

> “today announced updated interim data including up to 30 months of follow-up from 39 patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Derivation of the Enroll-HD external control arm analysis set

| Step | Participants |
| --- | --- |
| Diagnosis of HD in ENROLL-HD | “N = 19,542” |
| Met AMT-130 eligibility criteria | “N = 6,596 (33.8%)” |
| Did not meet AMT-130 eligibility criteria | “N = 12,946” |
| Excluded from the analysis set | “N = 3,326” |
| External control arm analysis set | “N = 3,270 (49.6%)” |
| Propensity-score matched to High-Dose cohort | “N = 940” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Analysis method for the primary and key secondary endpoints

> “LSM change from baseline at 3 years (±SE; MMRM)”
> “Above graph represents weighted observed data”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Primary and post hoc comparisons in the 48-month analysis

> “Primary Analysis (compared to Enroll-HD B)”
> “Post Hoc Analysis (compared to Enroll-HD A)”
> “48-Month Completers Only (n=12)”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Safety analysis set and adverse event definitions, June 2025 data cutoff

> “TEAEs are defined as AEs after Day 0.”
> “Perioperative AEs had onset Day 0 to 13. Safety data as of June 30, 2025; &1 low dose and 3 high dose cross-over patients included”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Follow-up at the three-year data cutoff

> “n = 12 had 3 years of follow-up as of June 30, 2025”
> “n = 583 from Enroll-HD had 3 years of post-eligibility follow-up”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Lumbar puncture declined at 36 months

> “1 of 12 patients declined to undergo a lumbar puncture procedure”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographic and baseline characteristics of the high-dose cohort and the propensity score-matched external control

| Characteristic, mean (SD) | AMT-130 high dose (N=17) | PSM external control, Enroll-HD (N=940) |
| --- | --- | --- |
| Sex, males (%) | “47.1” | “55.6” |
| Age | “45.8” | “45.2” |
| CAG repeats | “42.4” | “42.8” |
| CAP100 score | “86.2” | “86.8” |
| DCL = 3, 4 (%) | “35.3, 64.7” | “30.5, 69.5” |
| PIN score | “0.77” | “0.81” |
| cUHDRS | “14.9” | “14.7” |
| TFC | “12.2” | “12.1” |
| SDMT | “46.1” | “45.3” |
| SWRT | “89.9” | “87.6” |
| TMS | “12.1” | “11.6” |
| HD-ISS Stage 2, 3 (%) | “47.1, 52.9” | “51.6, 48.4” |
| Region; No. America, Other (%) | “58.8, 41.2” | “28.9, 71.1” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Sponsor assessment of baseline balance

> “The propensity score-matched external control has well-matched baseline characteristics to the patients treated with high-dose AMT-130.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Baseline scores of the treated cohorts, December 2023

> “composite Unified Huntington’s Disease Rating Scale (cUHDRS): AMT-130 showed a favorable difference in cUHDRS of 0.39 points at 30 months and 1.24 points at 18 months for the low- and high-dose, respectively (baseline values: 14.1 in low-dose and 14.9 in high-dose).”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary endpoint at 36 months: cUHDRS, high dose

> “A statistically significant 75% slowing of disease progression as measured by cUHDRS (p=0.003), which met the primary endpoint of the study. Treated patients had a mean change in cUHDRS from baseline of -0.38 compared to a change of -1.52 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-2"></a>

##### Key secondary endpoint at 36 months: TFC, high dose

> “A statistically significant 60% slowing of disease progression as measured by TFC (p=0.033), which met a key secondary endpoint of the study. Treated patients had a mean change in TFC from baseline of -0.36 compared to a change of -0.88 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-3"></a>

##### Other secondary endpoints at 36 months: SDMT, high dose

> “Favorable trends in other secondary endpoint measures of motor and cognitive function, including Symbol Digit Modalities Test (SDMT), Stroop Word Reading Test (SWRT) and Total Motor Score (TMS).”
> “An 88% slowing of disease progression as measured by SDMT (p=0.057), with a mean change in SDMT from baseline of -0.44 compared to a change of -3.73 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-4"></a>

##### Other secondary endpoints at 36 months: SWRT and TMS, high dose

> “A 113% slowing of disease progression as measured by SWRT (nominal p=0.002), with a mean change in SWRT from baseline of 0.88 compared to a change of -6.98 for patients in the propensity score-matched external control.”
> “A 59% slowing of disease progression as measured by TMS (nominal p=0.174), with a mean change in TMS from baseline of 2.01 compared to a change of 4.88 for patients in the propensity score-matched external control.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.1.8.3-5"></a>

##### Results at 36 months, low dose

| Endpoint | AMT-130 low dose (N=12), LSM change (SE) | Enroll-HD PSM external control, LSM change (SE) | External control N | LSM difference [95% CI] | Slowing of disease progression (%) | P-value |
| --- | --- | --- | --- | --- | --- | --- |
| cUHDRS | “-1.65 (0.411)” | “-1.72 (0.151)” | “N=383” | “0.07  [-0.75, 0.88]” | “3.9” | “0.871” |
| TFC | “-0.33 (0.296)” | “-1.04 (0.120)” | “N=392” | “0.71  [0.12, 1.31]” | “68.1” | “0.019” |
| SDMT | “-6.44 (1.532)” | “-3.35 (0.503)” | “N=387” | “-3.09  [-6.14, -0.05]” | “-92.3” | “0.046” |
| SWRT | “-3.67 (4.134)” | “-5.20 (1.373)” | “N=387” | “1.44 [-7.45, 10.33]” | “27.7” | “0.751” |
| TMS | “8.64 (2.039)” | “5.61 (0.688)” | “N=392” | “3.02 [-1.23, 7.28]” | “-53.9” | “0.163” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

> “P-value is nominal; hierarchical testing was discontinued for p-value >0.05”
> “Patients receiving low-dose AMT-130 showed variable trends in functional, motor and cognitive endpoints, suggestive of a dose-dependent effect”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Dose response and sensitivity analyses at 36 months

> “The Company believes that the consistently favorable results in functional, motor and cognitive endpoints at 36 months observed in the high dose group, compared to the variable trends observed in the low dose group, reflect a dose-dependent response to AMT-130.”
> “Various other supportive analyses of the results from the AMT-130 high dose treatment group, including those using a propensity score-weighted external control and comparisons to the TRACK-HD and PREDICT-HD datasets, were consistent with the primary analysis.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-7"></a>

##### Supportive endpoint at 36 months: cerebrospinal fluid neurofilament light chain

> “A mean reduction from baseline in cerebrospinal neurofilament light protein (CSF NfL) of -8.2%.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

| Group | Participants | Change in mean CSF NfL from baseline (%) |
| --- | --- | --- |
| AMT-130 high dose | “N=11” | “- 8.2” |
| AMT-130 low dose | “N=12” | “- 4.7” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.3-8"></a>

##### Cerebrospinal fluid neurofilament light chain at 2 and 3 years, high dose

| Timepoint | Participants | CSF NfL mean change from baseline |
| --- | --- | --- |
| Year 2 | “N = 15” | “-9.7%” |
| Year 3 | “N = 11” | “-8.2%” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.3-9"></a>

##### Updated 36-month analysis: cUHDRS and TFC, high dose (n=15)

> “cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients had a mean change in cUHDRS from baseline of -0.28 compared to a change of -1.39 for the external control, a favorable treatment difference of 1.12 compared to baseline.”
> “TFC showed 67% slowing of disease progression compared to the updated external control (nominal p=0.011). Treated patients had a mean change in TFC from baseline of -0.27 compared to a change of -0.82 for patients in the propensity score-matched external control, a favorable treatment difference of 0.55 compared to baseline.”
> “Mean cerebrospinal neurofilament light protein (CSF NfL) was 6% below baseline (n=14).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-10"></a>

##### Updated 36-month analysis: other secondary endpoints, high dose

| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD B (N=1337), LSM change | Slowing of disease progression | P-value |
| --- | --- | --- | --- | --- |
| SDMT | “0.67” | “-2.78” | “Slowed HD progression by 124% based on SDMT” | “p=0.040” |
| SWRT | “1.32” | “-5.75” | “Slowed HD progression by 123% based on SWRT” | “p=0.047” |
| TMS | “1.93” | “4.77” | “Slowed HD progression by 59% based on TMS” | “p=0.114” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “p-values are nominal”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-11"></a>

##### Primary analysis at 48 months: cUHDRS and TFC, high dose (n=12)

> “cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Treated patients had a mean change in cUHDRS from baseline of -0.90 compared to a change of -1.61 for the external control, a favorable treatment difference of 0.71 compared to baseline.”
> “TFC showed 61% slowing of disease progression compared to the updated external control (nominal p=0.008). Treated patients had a mean change in TFC from baseline of -0.37 compared to a change of -0.94 for the external control, a favorable treatment difference of 0.57 compared to baseline.”
> “Mean cerebrospinal neurofilament light protein (CSF NfL) was 4% above baseline (n=11).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-12"></a>

##### Primary analysis at 48 months: other secondary endpoints, high dose

| Endpoint | AMT-130 high dose (N=12), LSM change | Enroll-HD B, LSM change | Enroll-HD B N | Slowing of disease progression | P-value |
| --- | --- | --- | --- | --- | --- |
| SDMT | “-2.75” | “-3.43” | “Enroll-HD B (N=634)” | “Slowed HD progression by 20% based on SDMT” | “p=0.731” |
| SWRT | “0.95” | “-7.53” | “Enroll-HD B (N=633)” | “Slowed HD progression by 113% based on SWRT” | “p=0.006” |
| TMS | “4.82” | “5.10” | “Enroll-HD B (N=631)” | “Slowed HD progression by 5.6% based on TMS” | “p=0.908” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-13"></a>

##### Post hoc analysis at 48 months against the prior Enroll-HD external control

> “In a post-hoc sensitivity analysis using the prior ENROLL-HD external control, the 48-month analysis showed 53.5% slowing based on cUHDRS (nominal p=0.041) and 68.3% based on TFC (nominal p=0.001).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD A (N=619), LSM change | Slowing of disease progression |
| --- | --- | --- | --- |
| cUHDRS | “-0.90” | “-1.94” | “54% slowing of disease progression at 48 months (p=0.041” |
| TFC | “-0.39” | “-1.24” | “68% slowing of disease progression at 48 months (p<0.001” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-14"></a>

##### Dose comparison at 48 months

> “The observed differences between the high and low doses are consistent with a dose-dependent treatment effect. At 48 months, mean change from baseline in cUHDRS was –0.91 in high-dose patients compared with −1.94 in low-dose patients, a difference of 1.03 in favor of the high dose. Mean change from baseline in TFC was −0.30 in high-dose patients compared with −0.70 in low-dose patients, a difference of 0.40 in favor of the high dose.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-15"></a>

##### Cerebrospinal fluid neurofilament light chain through 48 months, both doses

> “CSF NfL levels maintained near baseline starting from Month 18 and up to 4 years”
> “Mean CSF NfL was 4% above baseline for the high-dose and 8% below baseline for the low-dose at Month 48”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-16"></a>

##### Interim results at 24 months against the propensity-weighted external control, July 2024

> “At 24 months, the mean change in cUHDRS for patients receiving the high-dose of AMT-130 was -0.2 compared to -1.0 for patients in the propensity score-weighted external control, representing an 80% slowing of disease progression (p=0.007).”
> “At 24 months, the mean change in cUDHRS for patients receiving the low-dose of AMT-130 was -0.7 compared to -1.0 for patients in the propensity score-weighted external control, representing a 30% slowing of disease progression (p=0.21).”
> “Patients treated with AMT-130 had a mean reduction in CSF NfL of 11% compared to baseline (p=0.02) at 24 months.”
> “Mean CSF NfL levels for both high and low doses were below baseline at 24 months.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.8.3-17"></a>

##### Interim results against the criteria-matched TRACK-HD cohort, December 2023

> “Total Functional Capacity (TFC): AMT-130 showed a favorable difference in TFC of 0.95 points at 30 months in the low-dose and 0.49 points at 18 months in the high-dose (baseline values: 11.9 in low-dose and 12.2 in high-dose).”
> “Total Motor Score (TMS): AMT-130 showed a favorable difference in TMS of 2.80 points at 30 months in the low-dose and 1.70 points in the high-dose at 18 months (baseline values: 13.3 in low-dose and 12.1 in high-dose).”
> “Neurofilament Light Chain (NfL): Mean CSF NfL for the low-dose cohort remained below baseline through month 30 and was 6.6% below baseline. Mean CSF NfL for the high-dose cohort also further declined and is near baseline at month 18.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Safety summary at the three-year data cutoff

> “AMT-130 was generally well-tolerated, with a manageable safety profile at both doses. As of June 30, 2025, no new drug-related serious adverse events have been observed since December 2022. The most common adverse events in the treatment groups were related to the administration procedure, which all resolved.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.5-2"></a>

##### Timing and resolution of drug-related serious adverse events

> “The majority of drug-related serious adverse events occurred within the first weeks post treatment and fully resolved with steroids or supportive care”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.5-3"></a>

##### Adverse events in Cohorts 1 to 3, June 2025 data cutoff

| Adverse event, N (%) | Sham surgery (n=10) | Low-dose AMT-130, Cohort 1 (n=13) | High-dose AMT-130, Cohort 2 (n=20) | Dose-blinded, Cohort 3 (n=12) | All AMT-130, Cohorts 1, 2 and 3 (n=45) |
| --- | --- | --- | --- | --- | --- |
| Any TEAEs | “10” (“100.0”) | “12” (“92.3”) | “20” (“100.0”) | “12” (“100”) | “44” (“97.8”) |
| Any SAEs | “1” (“10.0”) | “3” (“23.1”) | “9” (“45.0”) | “3” (“25”) | “15” (“33.3”) |
| Any SAEs (peri-operative) | “1” (“10.0”) | “2” (“15.4”) | “6” (“30.0”) | “0” (“0.0”) | “8” (“17.8”) |
| Any drug-related TEAE | “0” (“0.0”) | “0” (“0.0”) | “6” (“30.0”) | “3” (“25.0”) | “9” (“20.0”) |
| Any drug-related SAE | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “0” (“0.0”) | “4” (“8.8”) |
| Headache | “3” (“30.0”) | “3” (“23.1”) | “9” (“45.0”) | “6” (“50.0”) | “18” (“40.0”) |
| Procedural headache | “5” (“50.0”) | “4” (“30.8”) | “10” (“50.0”) | “2” (“16.7”) | “16” (“35.6”) |
| Procedural pain | “6” (“60.0”) | “2” (“15.4”) | “7” (“35.0”) | “2” (“16.7”) | “11” (“24.4”) |
| Post lumbar puncture syndrome | “6” (“60.0”) | “2” (“15.4”) | “5” (“25.0”) | “2” (“16.7”) | “10” (“22.2”) |
| Procedural complication | “4” (“40.0”) | “4” (“30.8”) | “5” (“25.0”) | “0” (“0.0”) | “9” (“20.0”) |
| Anxiety | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “4” (“33.3”) | “8” (“17.8”) |
| Constipation | “0” (“0.0”) | “0” (“0.0”) | “2” (“10.0”) | “6” (“50.0”) | “8” (“17.8”) |
| Insomnia | “0” (“0.0”) | “1” (“7.7”) | “1” (“5.0”) | “6” (“50.0”) | “8” (“17.8”) |
| Back pain | “1” (“10.0”) | “0” (“0.0”) | “0” (“0.0”) | “5” (“41.7”) | “5” (“11.1”) |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.5-4"></a>

##### Reclassified serious adverse event and most common adverse events, June 2025 data cutoff

> “One SAE reported as “tension headache” was retrospectively considered by uniQure as a case of CNS inflammation.”
> “Most common AEs (≥20%): Headache, procedural pain, post-lumbar puncture syndrome”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.5-5"></a>

##### Safety summary at the four-year data cutoff

> “Ifezuntirgene inilparvovec continues to be generally well-tolerated, with a manageable safety profile at both doses. The most common adverse events in the treatment groups were related to the administration procedure, and all have resolved. As previously disclosed, five high dose participants (17%) experienced a treatment-related serious adverse event (SAE) related to central nervous system inflammation, all of which fully resolved.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

> “No new treatment-related serious adverse events (SAE) reported in Cohorts 1 and 2”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Suicide in a low-dose participant

> “Since the September 2025 data readout, one suicide in a low-dose patient occurred, approximately five years after receiving treatment. This was assessed as unrelated to treatment by the study investigator.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.5-7"></a>

##### Adverse events in all 51 treated participants, June 2026 data cutoff

| Adverse event, N (%) | Sham surgery (n=10) | Low-dose AMT-130, Cohort 1 (n=13) | High-dose AMT-130, Cohort 2 (n=20) | Dose-blinded AMT-130, Cohort 3 (n=12) | High-dose AMT-130, Cohort 4 (n=6) | All AMT-130, Cohorts 1, 2, 3 and 4 (n=51) |
| --- | --- | --- | --- | --- | --- | --- |
| Any TEAEs | “10” (“100.0”) | “12” (“92.3”) | “20” (“100.0”) | “12” (“100”) | “6” (“100”) | “50” (“98”) |
| Any SAEs | “1” (“10.0”) | “4” (“30.8”) | “10” (“50.0”) | “4” (“33.3”) | “2” (“33”) | “20” (“39.2”) |
| Any SAEs (peri-operative) | “1” (“10.0”) | “2” (“15.4”) | “6” (“30.0”) | “0” (“0.0”) | “1” (“16.7”) | “9” (“17.6”) |
| Any drug-related TEAE | “0” (“0.0”) | “0” (“0.0”) | “6” (“30.0”) | “3” (“25.0”) | “2” (“33.3”) | “11” (“21.5”) |
| Any drug-related SAE | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “0” (“0.0”) | “1” (“16.7”) | “5” (“9.80”) |
| Headache | “3” (“30.0”) | “2” (“15.4”) | “9” (“45.0”) | “6” (“50.0”) | “4” (“66.7”) | “21” (“41.2”) |
| Procedural headache | “5” (“50.0”) | “4” (“30.8”) | “10” (“50.0”) | “2” (“16.7”) | “0” (“0.0”) | “16” (“31.4”) |
| Procedural pain | “6” (“60.0”) | “2” (“15.4”) | “7” (“35.0”) | “3” (“25.0”) | “1” (“16.7”) | “13” (“25.5”) |
| Post lumbar puncture syndrome | “6” (“60.0”) | “2” (“15.4”) | “6” (“30.0”) | “2” (“16.7”) | “0” (“0.0”) | “10” (“19.6”) |
| Procedural complication | “4” (“40.0”) | “3” (“23.1”) | “4” (“20.0”) | “0” (“0.0”) | “0” (“0.0”) | “7” (“13.7”) |
| Anxiety | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “4” (“33.3”) | “3” (“50.0”) | “11” (“21.6”) |
| Constipation | “0” (“0.0”) | “0” (“0.0”) | “2” (“10.0”) | “6” (“50.0”) | “1” (“16.7”) | “9” (“17.6”) |
| Insomnia | “0” (“0.0”) | “1” (“7.7”) | “1” (“5.0”) | “6” (“50.0”) | “2” (“33.3”) | “10” (“19.6”) |
| Back pain | “1” (“10.0”) | “0” (“0.0”) | “0” (“0.0”) | “5” (“41.7”) | “0” (“0.0”) | “5” (“9.8”) |
| Procedural nausea | “0” (“0.0”) | “3” (“23.1”) | “3” (“15.0”) | “1” (“8.3”) | “2” (“33.3”) | “9” (“17.6”) |
| Paraesthesia | “1” (“10.0”) | “0” (“0.0”) | “1” (“5.0”) | “1” (“8.3”) | “2” (“33.3”) | “4” (“7.8”) |
| Sleep disorder | “0” (“0.0”) | “0” (“0.0”) | “0” (“0.0”) | “4” (“33.3”) | “0” (“0.0”) | “4” (“7.8”) |
| Sensory loss | “0” (“0.0”) | “0” (“0.0”) | “0” (“0.0”) | “1” (“8.3”) | “2” (“33.3”) | “3” (“5.9”) |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “TEAEs are defined as AEs on or after Day 0.”
> “Safety data as of June 30, 2026; * 1 low dose and 3 high dose cross-over patients included”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.5-8"></a>

##### Safety at the 24-month interim analysis, July 2024

> “Based on data observed to date, AMT-130 remains generally well-tolerated, with a manageable safety profile at both doses. There were no new AMT-130-related serious adverse events reported.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.8.5-9"></a>

##### Serious adverse events across both studies, December 2023

> “There were four serious adverse events (SAE) unrelated to AMT-130 (post-operative delirium, major depression, suicidal ideation and epistaxis) in the low-dose cohort, six unrelated SAEs in the high-dose cohort (back pain, hypothermia, post procedural hematoma, post-lumbar puncture syndrome (n=2), pulmonary embolism), and one SAE (deep vein thrombosis) in the control group.”
> “In addition, there were four AMT-130-related serious adverse events in the high-dose cohort (central nervous system inflammation (n=3), and severe headache (1) that, retrospectively, also was attributable to central nervous system inflammation.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- External comparison: efficacy is assessed against a propensity score-matched external control from the Enroll-HD natural history data set. The Form 10-K states that the analyses rely on external historical controls and that these may not be accepted as a basis for regulatory approval. After a Type A meeting in January 2026, the FDA stated that it cannot agree that these data are sufficient as primary evidence of effectiveness. One commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”.
- Open-label treatment: the same commentary noted that most participants were in open-label arms, so a placebo effect is possible. An analysis of the GENERATION HD1 placebo arm found a placebo response on the cognitive scores (SDMT and SWR), which also influences the cUHDRS.
- Matching covariates: MRI data were not collected in Enroll-HD, so striatal volume, a predictor of decline and an eligibility criterion of the phase I/II studies, could not be matched. The sponsor analysis used baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR and reports that other covariates can substitute for striatal volume. A comment submitted to ICER listed limits of the natural history comparison, including bias from selection into a surgical trial versus a registry, different visit schedules, and very small numbers of treated patients at longer follow-up.
- Small numbers: 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; CSF NfL was available for 11 high-dose participants at 36 months in the three-year analysis.
- Missing data and changes in the control: missingness in the updated Enroll-HD matched controls reached 53% at 48 months, controls with longer follow-up declined more slowly, and decline in Enroll-HD B was 20% slower than in Enroll-HD A at 48 months. Against Enroll-HD B the 48-month cUHDRS result did not reach statistical significance (p=0.144); the result against Enroll-HD A comes from a post-hoc sensitivity analysis. A news report on the four-year analysis noted that the natural history database is updated, which “can alter results”.
- Analysis choices and nominal p-values: the June 2025 release described a propensity score-weighted primary analysis, while the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis. The 24-month comparison with a propensity-weighted external control of 154 participants was a post-hoc analysis. Several p-values are nominal, which the Form 10-K states regulators may weigh less than standard p-values.
- Reporting: the results are reported in company press releases, presentations, and SEC filings. One commentary noted that individual data points are not shown, error bars are not defined, data from imitation (sham) procedure participants are not shown, and there are no data on mutant HTT lowering.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.9-2"></a>

#### Sponsor-disclosed risks of external controls, post hoc analyses, and nominal p-values

> “For example, in conjunction with our July 2024 interim data update for AMT-130, we conducted a post-hoc analysis of clinical outcomes for the 21 treated patients at 24 months compared to an expanded, propensity-weighted external control consisting of 154 patients.”
> “In addition, analyses of our clinical trial data may, and do, rely on external historical controls, rather than blinded, placebo-controlled comparator populations, which may not be accepted as a basis for regulatory approval.”
> “Nominal p-values are subject to certain limitations, and because of these limitations, regulatory authorities may give less weight to nominal p-values, compared to standard p-values.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.1.9-3"></a>

#### Missing data and survivor bias in the updated Enroll-HD external control

> “As is common with longitudinal natural history studies, missingness of data increased with duration of follow-up, reaching 53% in the updated ENROLL-HD matched controls at 48 months. The Company’s analysis of the updated control showed that patients discontinuing follow-up were progressing materially faster than those remaining in the control group. The Company believes these factors likely understated disease progression in the control and the resulting treatment effect of ifezuntirgene inilparvovec at 48 months.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

| Enroll-HD B participants, by last available data | Annualized cUHDRS change from baseline |
| --- | --- |
| Participants with last data at Y1 | “-0.91” |
| Participants with last data at Y2 | “-0.82” |
| Participants with last data at Y3 | “-0.73” |
| Participants with last data at Y4 or more | “-0.41” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “Participants with longer follow up declined more slowly, enriching the comparator with slower progressors”
> “Data missingness in Enroll-HD B reached 53% at Month 48”
> “These effects were more evident in Enroll-HD B than in Enroll-HD A”
> “At 48 months, Enroll-HD B decline was 20% slower than Enroll-HD A”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.9-4"></a>

#### Absence of striatal volume data in Enroll-HD

> “MRI data were not collected as part of Enroll-HD protocol”
> “Without correction for other baseline characteristics, participants with high striatal volume tended to have slower clinical and MRI progression”
> “Previous studies have indicated that striatal volume is predictive of decline, this was replicated in the TRACK-HD/TRACK-ON/PREDICT-HD combined cohort”
> “However, propensity score analysis supported that other covariates can be substituted to adjust for the effect of striatal volume on cUHDRS & TFC outcomes”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.9-5"></a>

#### Effect of volumetric criteria on 3-year decline in TRACK-HD, TRACK-ON, and PREDICT-HD

| Analysis | Volumetric criteria applied (N = 232) | Volumetric criteria not applied (N = 442) |
| --- | --- | --- |
| cUHDRS mean change from baseline to 3 years, unweighted | “-1.4” | “-1.7” |
| cUHDRS mean change from baseline to 3 years, PS weighted | “-1.4” | “-1.4” |
| TFC mean change from baseline to 3 years, unweighted | “-1.0” | “-1.2” |
| TFC mean change from baseline to 3 years, PS weighted | “-0.9” | “-0.9” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “Baseline Volumetric Criteria Are No Longer Predictive of cUHDRS Decline When Propensity Score Adjustments Are Applied”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.9-6"></a>

#### Independent commentary on the external control comparison, October 2025

> “As you can appreciate, the evidence of efficacy here depends entirely on the ENROLL-HD controls being well-matched.”
> “Most of the patients in the Uniqure trial were in open label arms, so there could be some placebo effect, perhaps mediated by belief in the therapy and greater effort to do well on the tests.”
> “Individual data points are not shown in any of the plots; error bars are shown but never defined.”
> “The data from imitation/sham procedure patients are not shown and their absence is not explained.”
> “There are no data on target engagement (mutant HTT lowering), which would greatly inform our prior for whether the therapy worked.”

Source: [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/)

<a id="topic-3.1.1.9-7"></a>

#### Analyst commentary on the four-year analysis, September 2026

> “One is the natural history database, which presents some challenges. Not only does the database get updated, which can alter results, but more information can go missing the longer patients are followed.”

Source: [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
